Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphoid 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Ovarian Cancer 1

Interventions

fludarabine 4Rituximab 4ibrutinib 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Lenalidomide 3Cyclophosphamide 3Busulfan 3Bendamustine Hydrochloride 3fludarabine phosphate 2Patient Reported Outcome Measures 2Mesna 2venetoclax 1sargramostim 1pirtobrutinib 1ofatumumab 1mocetinostat 1lirilumab 1copanlisib 1Thiotepa 1Sirolimus 1RFT5-SMPT-dgA immunotoxin 1Mitoxantrone 1Methotrexate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphoid × Antineoplastic Agents × Clear all
NCT02462265 2018-04-18

Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

Oshadi Drug Administration

Phase 2 Suspended
15 enrolled
Other hematologic neoplasm

Leukemia, Lymphoid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡